| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Collaboration revenue | ||||||
104,391 | 7,619 | 10,135 | 14,220 | 17,334 | - | |
Operating expenses: | ||||||
Research and development | ||||||
119,735 | 64,905 | 62,260 | 42,249 | 27,679 | 8,898 | |
General and administrative | ||||||
36,335 | 33,809 | 19,738 | 13,270 | 9,909 | 5,469 | |
Total operating expenses | ||||||
156,070 | 98,714 | 81,998 | 55,519 | 37,588 | 14,367 | |
Operating loss | ||||||
-51,679 | -91,095 | -71,863 | -41,299 | -20,254 | -14,367 | |
Other income: | ||||||
Interest income | ||||||
6,457 | 3,310 | 1,227 | 976 | 332 | -1 | |
Other (expense) income | ||||||
1,625 | -683 | -62 | 182 | -9,750 | -1,949 | |
Total other income | ||||||
8,082 | 2,627 | 1,165 | 1,158 | -9,418 | -1,950 | |
Loss before income taxes | ||||||
-43,597 | -88,468 | -70,698 | -40,141 | -29,672 | -16,317 | |
Income tax benefit | ||||||
- | -180 | - | 52 | - | - | |
Net loss | ||||||
-43,597 | -88,288 | -70,698 | -40,193 | -29,672 | -16,317 | |
Other comprehensive income | ||||||
Net unrealized gain on available-for-sale-securities | ||||||
29 | 34 | -235 | 199 | -251 | - | |
Total other comprehensive income | ||||||
29 | 34 | -235 | 199 | -251 | - | |
Comprehensive loss | ||||||
-43,568 | -88,254 | -70,933 | -39,994 | -29,923 | -16,317 | |
Reconciliation of net loss to net loss attributable to common stockholders: | ||||||
Accretion of redeemable convertible preferred stock to redemption value | ||||||
- | - | - | - | 7,373 | 1,366 | |
Accrued dividends on series A preferred stock | ||||||
- | - | - | - | 1,245 | - | |
Net loss attributable to common stockholders | ||||||
- | - | - | - | -38,290 | -17,683 | |
Net loss per share, basic and diluted | ||||||
-1.21 | -2.75 | -2.64 | -1.59 | 9.14 | 27.83 | |
Weighted-average common shares outstanding, basic and diluted | ||||||
35,898 | 32,065 | 26,803 | 25,302 | 4,191 | 635 | |